Medicilon honored with the 'Best Client Satisfaction Pharmaceutical CRO' at the 2024 VBEF."

On May 9th, the "2024 Top 100 Future Healthcare" series rankings were officially unveiled. Medicilon successfully made it onto the list and was awarded the "Best Client Satisfaction Pharmaceutical CRO" due to its outstanding market performance, human resources, knowledge resources, and essential partnership resources.

The "2024 Top 100 Future Healthcare" list was jointly launched by vbdata.cn, VB100, and VCBeat Research, aiming to select truly representative Chinese innovative medical practitioners who embody the future of healthcare and drive the innovative transformation process in the health and medical industry. This selection process, with a strict and fair evaluation mechanism, combines multiple stages including independent company applications, professional evaluations, cross-evaluations by supporting organizations, and final review by an expert committee. It focuses on the growth and annual performance of candidate companies across 17 secondary indicators under four primary indicators: human resources, knowledge resources, important partnership resources, and market performance. It provides authoritative and objective evaluation criteria and systems for the innovation industry in China's health and medical sectors.